Open Label Trial to Evaluate the Adhesion of TK-254RX in Healthy Volunteers.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-14

Study Completion Date

2023-12-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multi center, multiple dose, open label trial to evaluate the adhesion of TK-254RX in healthy volunteers. The primary purpose of this study is to evaluate the adhesion of TK-254RX. Secondary purpose is to show TK-254RX is safe and to explore and compare adhesion assessment methods.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults

NCT02221726

Healthy

COMPLETED EARLY_PHASE1

Controlled Randomized Study With Athena Base Plate Versus SenSura Base Plate on Perspiring Skin

NCT01245413

Healthy

COMPLETED NA

Evaluation of Safety and Tolerability of Libella Gene Therapy for the Treatment of Aging: AAV- hTERT

NCT04133649

Aging

UNKNOWN PHASE1

Discrete(TM) Safety Clinical Trial GLAD-01

NCT04034784

Safety and Tolerability in Healthy Volunteers

COMPLETED NA

Tolerance and Practicality of Module AOX

NCT00425529

Gastrointestinal Diseases Nutrition

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TK-254RX applied to Lower Arm, Lower thigh or Ankle

For Group1, TK-254RX will be applied to left and right side (total of two TK-254RX per day) of the following predetermined application site by subjects.

Day1: Lower Arm, Day2: Lower thigh, Day3: Ankle

Group Type EXPERIMENTAL

TK-254RX

Intervention Type DRUG

Two TK-254RX per day to predetermined application site

TK-254RX applied to Upper Arm, Upper thigh or Lower leg

For Group2, TK-254RX will be applied to left and right side (total of two TK-254RX per day) of the following predetermined application site by subjects.

Day1: Upper Arm, Day2: Upper thigh, Day3: Lower leg

Group Type EXPERIMENTAL

TK-254RX

Intervention Type DRUG

Two TK-254RX per day to predetermined application site

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TK-254RX

Two TK-254RX per day to predetermined application site

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age: 18 to 64 years
* good state of health
* non-smoker or ex-smoker for at least 3 months
* written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial

Exclusion Criteria

The following must not apply:

* any injury of body which may induce the restriction of body movement
* excessively hairy skin at application site
* current skin disorder or shaving hair at application site
* history of excessive sweating/hyperhidrosis inclusive of application site
* participation in a clinical study within 30 days before inclusion in the study or concomitantly
* drug or alcohol abuse in the opinion of the investigator
* pregnant and lactating women
* women of child-bearing potential who do not agree to apply highly effective contraceptive methods
* known hypersensitivity to active ingredient, its racemate or one of the excipients of the TK-254RX
* existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
* existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
* known liver or kidney insufficiency
* existing gastrointestinal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
* history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
* systolic blood pressure \< 90 or \> 139 mmHg
* diastolic blood pressure \< 60 or \> 89 mmHg
* pulse rate \< 50 bpm or \> 90 bpm
* subjects who use any impermissible medication

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes